Helix BioPharma Corp. (TSX: HBP)
Health Care · Biotechnology · CA
CA$2.01
+2.03% today · +45.9% 1Y
Helix BioPharma Corp. (TSX: HBP) operates in the Biotechnology industry within the Health Care sector. The company is valued at $109.28M and employs 7 people.
Over the last twelve months the share price has gained 45.9%, trading between 1.10 and 5.40.
Tweenvest scores Helix BioPharma Corp. across four factors: quality 28/100. Its strongest factor is quality.
HBP price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $109.28M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.04
- Dividend yield
- —
- Beta (5Y)
- -0.35
- 52-week high
- CA$5.40
- 52-week low
- CA$1.10
- Avg volume (3M)
- —
- Shares outstanding
- 76.38M
- Employees
- 7
- Next earnings
- —
About Helix BioPharma Corp.
Based in Richmond Hill, Canada, Helix BioPharma Corp. is a Canadian immune-oncology company focused on therapeutic development. The firm is progressing L-DOS47 for treating non-small cell lung cancer and is also working on V-DOS47, which targets the vascular epithelial growth factor receptor 2. Helix BioPharma has formed strategic alliances, including one with Moffitt Cancer Center to analyze L-DOS47's pharmacodynamics and assess the benefits of integrating it with immune checkpoint inhibitors. Another partnership, with ProMab Biotechnologies, Inc., is dedicated to creating innovative antibody and chimeric antigen receptor T-cell therapies to combat multiple myeloma. Furthermore, the company maintains licensing agreements with Xisle Pharma Ventures Trust and the National Research Council Canada.
- ISIN
- CA4229102088
- Founded
- 2008
- Listed since
- Aug 13, 1996
- Exchange
- The Toronto Stock Exchange
- Currency
- CAD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €864.20 | -4.19% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $138.89 | -4.26% |
Figures last refreshed Aug 18, 2026.